加拿大Medtronic CryoCath Technologies Inc., (蒙特利尔，Montreal)   
美敦力3.8亿美元收购CryoCath强化房颤领域 CryoCath公司主要生产房颤等心血管疾病冷冻消融治疗法所用的冷冻系统。房颤是一种较常见的心率失常。房颤的治疗是心率疾病治疗市场中增长最迅速的部分。目前，该领域的领先者是美敦力的竞争对手St.Jude医疗器械公司
CryoCath is a medical technology company that leads the world in creating catheter- and probe-based CryoTherapy products to treat cardiovascular disease. Traditionally, the use of freezing temperatures to treat diseased tissue has been limited by the inability to deliver the treatment in a minimally invasive manner. We have successfully overcome this obstacle by developing flexible, steerable, minimally invasive catheters to deliver cold therapy safely and effectively.

Our CryoTherapy Revolution
CryoCath has blazed a trail in CryoTherapy and continues to do so with the successful U.S. launch of Freezor®, a cryocatheter for the treatment of AVNRT. To get a better idea of where we've come from and where we're going, take a look at other important company milestones.

A Culture of Leadership, Integrity and Respect
We believe that the only way for us to maintain our leadership is through empowerment, inspiration, teamwork and conviction. And as important as our R&D and commercial successes are, we are also driven by our ability to improve peoples lives profoundly through our clinical innovations.